| Bioactivity | Napyradiomycin B4 is a Napyradiomycin derivative, which inhibits the RANKL-induced MEK-ERK signaling pathway. Napyradiomycin B4 attenuates osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis[1]. |
| Invitro | Napyradiomycin B4 (5 μM, 4 days) 抑制 RANKL 诱导的破骨细胞分化[1]。Napyradiomycin B4 (5 μM, 4 days) 促进 Nrf2 相关基因的表达并抑制破骨细胞相关基因的表达[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Napyradiomycin B4 相关抗体: Immunofluorescence[1] Cell Line: |
| In Vivo | Napyradiomycin B4 (2-12 mg/kg，腹腔注射，6 天) 对破骨细胞介导的骨质流失具有保护作用，在 C57BL/J6 小鼠模型中通过抑制破骨细胞形成来防止牙周骨质破坏，且无明显毒性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C25H31Cl3O6 |
| Molar Mass | 533.87 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kim JA, et al., Napyradiomycin B4 Suppresses RANKL-Induced Osteoclastogenesis and Prevents Alveolar Bone Destruction in Experimental Periodontitis. ACS Pharmacol Transl Sci. 2024 Apr 3;7(4):1023-1031. |